The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 21, 2021

Filed:

Mar. 23, 2017
Applicants:

The Broad Institute, Inc., Cambridge, MA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

Inventors:

Phillip A. Sharp, Newton, MA (US);

Feng Zhang, Cambridge, MA (US);

Randall Jeffrey Platt, Basel, CH;

Sidi Chen, Milford, CT (US);

Assignees:

The Broad Institute, Inc., Cambridge, MA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/63 (2006.01); A01K 67/027 (2006.01); C12N 15/85 (2006.01); C12N 15/11 (2006.01); C12N 9/22 (2006.01); C12N 15/10 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12N 15/63 (2013.01); A01K 67/0275 (2013.01); C12N 9/22 (2013.01); C12N 15/102 (2013.01); C12N 15/111 (2013.01); C12N 15/85 (2013.01); C12N 15/8509 (2013.01); C12N 15/907 (2013.01); A01K 2217/00 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0306 (2013.01); A01K 2267/0331 (2013.01); C12N 2310/20 (2017.05); C12N 2310/3519 (2013.01); C12N 2310/531 (2013.01); C12N 2320/10 (2013.01); C12N 2320/32 (2013.01); C12N 2750/14143 (2013.01); C12N 2830/48 (2013.01);
Abstract

The invention involves inducing 3-50 or more mutations (e.g., any whole number between 3 and 50 of mutations, with it noted that in some embodiments there can be up to 16 different RNA(s), e.g., sgRNAs each having its own a promoter, in a vector, such as AAV, and that when each sgRNA does not have its own promoter, there can be twice to thrice that amount of different RNA(s), e.g., sgRNAs, e.g., 32 or even 48 different guides delivered by one vector) in transgenic Cas9 eukaryotes to model genetic disease, e.g. cancer. The invention comprehends testing putative treatments with such models, e.g., testing putative chemical compounds that may be pharmaceutically relevant for treatment or gene therapy that may be relevant for treatment, or combinations thereof. The invention allows for the study of genetic diseases and putative treatments to better understand and alleviate a genetic disease or a condition, e.g., cancer.


Find Patent Forward Citations

Loading…